However, a recent study in sarcoma cell lines uncovered no synergistic effect of CDK4 and MDM2 inhibition and, on the contrary, CDK4 inhibition antagonised nutlin-3a and led to downregulation of p53 and its target genes [118]. The gene discussed is TP53; the disease is sarcoma.